Condition: Clear Cell Renal Cell Carcinoma · Renal Cell Carcinoma · RCC · Sponsor: Neomorph, Inc
The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monotherapy.
This description comes directly from the study's public registry record.
Sara Weymer · +1 858-428-9800 · clinicaltrials@neomorph.com
Always discuss trial participation with your own doctor first.
| NEO-811 Los Angeles Site | Duarte, California, United States | Recruiting |
| NEO-811 San Diego Site | San Diego, California, United States | Recruiting |
| NEO-811 Connecticut Site | New Haven, Connecticut, United States | Recruiting |
| NEO-811 Chicago Site | Zion, Illinois, United States | Recruiting |
| NEO-811 Grand Rapids Site | Grand Rapids, Michigan, United States | Recruiting |
| NEO-811 Long Island Site | Lake Success, New York, United States | Recruiting |
| NEO-811 NYC Site | New York, New York, United States | Recruiting |
| NEO-811 South Carolina Site | Myrtle Beach, South Carolina, United States | Recruiting |
| NEO-811 Dallas Site | Dallas, Texas, United States | Recruiting |
| NEO-811 Houston Site | Houston, Texas, United States | Recruiting |
| NEO-811 Virginia Site | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07300241